Frank von Sonnenburg1, Pamela Perona1, Ulf Darsow2, Johannes Ring2, Alfred von Krempelhuber3, Jens Vollmar4, Siegfried Roesch5, Nicole Baedeker5, Herwig Kollaritsch6, Paul Chaplin7. 1. Department of Infectious Diseases and Tropical Medicine, Section of International Medicine and Public Health, Ludwig-Maximilians-Universität, Munich, Germany. 2. Department of Dermatology and Allergy Biederstein, Technische Universität München and Division of Environmental Dermatology and Allergy, Helmholtz Center/TUM, Munich, Germany. 3. Bavarian Nordic GmbH, Martinsried, Germany. Electronic address: alfred.v.krempelhuber@gsk.com. 4. Bavarian Nordic GmbH, Martinsried, Germany. Electronic address: jens.j.vollmar@gsk.com. 5. Bavarian Nordic GmbH, Martinsried, Germany. 6. Department of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, Medical University Vienna, Vienna, Austria. 7. Bavarian Nordic GmbH, Martinsried, Germany. Electronic address: pch@bavarian-nordic.com.
Abstract
BACKGROUND: Following vaccination with traditional smallpox vaccines or after exposure to vaccinated individuals, subjects with atopic dermatitis (AD) can develop eczema vaccinatum, a severe disease with disseminated eruption of pustular contagious lesions. Alternative smallpox vaccines with an improved safety profile would address this unmet medical need. METHODS: An open-label controlled Phase I clinical trial was conducted to investigate the safety and immunogenicity of modified vaccinia Ankara (MVA) in 15 healthy subjects compared to 45 subjects with either mild allergic rhinitis, a history of AD or presenting with mild active AD. MVA was given (Week 0 and 4) by a subcutaneous injection during a 28-week observation period. RESULTS: No serious adverse event was reported and vaccinations with MVA did not lead to any clinically relevant skin reactions in AD subjects. Unsolicited administration site reactions did not show any trends compared to the healthy subject group. The majority of adverse reactions were mild to moderate, and all reactions were transient and resolved without intervention. The majority of vaccinees had seroconverted by ELISA (80-93%) and PRNT (69-79%) already two weeks after the first vaccination, increasing to 100% after the second immunization, with peak GMT above 1000 and 145 for ELISA and PRNT, respectively. CONCLUSIONS: MVA was equally well tolerated and immunogenic in all enrolled subjects with mild to moderate pain and redness at the injection site being the most frequent adverse reactions. There were no differences in the safety or immunogenicity profile of MVA in healthy subjects or those with AD or allergic rhinitis. The study has confirmed MVA as a promising smallpox vaccine candidate and demonstrated in a small study population that the vaccine has a similar safety and immunogenicity profile in healthy subjects and people with active AD. CLINICAL TRIALS REGISTRATION: NCT00189917.
BACKGROUND: Following vaccination with traditional smallpox vaccines or after exposure to vaccinated individuals, subjects with atopic dermatitis (AD) can develop eczema vaccinatum, a severe disease with disseminated eruption of pustular contagious lesions. Alternative smallpox vaccines with an improved safety profile would address this unmet medical need. METHODS: An open-label controlled Phase I clinical trial was conducted to investigate the safety and immunogenicity of modified vaccinia Ankara (MVA) in 15 healthy subjects compared to 45 subjects with either mild allergic rhinitis, a history of AD or presenting with mild active AD. MVA was given (Week 0 and 4) by a subcutaneous injection during a 28-week observation period. RESULTS: No serious adverse event was reported and vaccinations with MVA did not lead to any clinically relevant skin reactions in AD subjects. Unsolicited administration site reactions did not show any trends compared to the healthy subject group. The majority of adverse reactions were mild to moderate, and all reactions were transient and resolved without intervention. The majority of vaccinees had seroconverted by ELISA (80-93%) and PRNT (69-79%) already two weeks after the first vaccination, increasing to 100% after the second immunization, with peak GMT above 1000 and 145 for ELISA and PRNT, respectively. CONCLUSIONS: MVA was equally well tolerated and immunogenic in all enrolled subjects with mild to moderate pain and redness at the injection site being the most frequent adverse reactions. There were no differences in the safety or immunogenicity profile of MVA in healthy subjects or those with AD or allergic rhinitis. The study has confirmed MVA as a promising smallpox vaccine candidate and demonstrated in a small study population that the vaccine has a similar safety and immunogenicity profile in healthy subjects and people with active AD. CLINICAL TRIALS REGISTRATION: NCT00189917.
Authors: U Darsow; M Sbornik; S Rombold; K Katzer; F von Sonnenburg; H Behrendt; J Ring Journal: J Eur Acad Dermatol Venereol Date: 2016-06-29 Impact factor: 6.166
Authors: Margaret E Gatti-Mays; Julius Strauss; Jeffrey Schlom; James L Gulley; Renee N Donahue; Claudia Palena; Jaydira Del Rivero; Jason M Redman; Ravi A Madan; Jennifer L Marté; Lisa M Cordes; Elizabeth Lamping; Alanvin Orpia; Andrea Burmeister; Eva Wagner; Cesar Pico Navarro; Christopher R Heery Journal: Clin Cancer Res Date: 2019-05-20 Impact factor: 12.531
Authors: Christopher R Heery; Claudia Palena; Sheri McMahon; Renee N Donahue; Lauren M Lepone; Italia Grenga; Ulrike Dirmeier; Lisa Cordes; Jenn Marté; William Dahut; Harpreet Singh; Ravi A Madan; Romaine I Fernando; Duane H Hamilton; Jeffrey Schlom; James L Gulley Journal: Clin Cancer Res Date: 2017-08-30 Impact factor: 12.531
Authors: Richard N Greenberg; Maria Yadira Hurley; Yadira Hurley; Dinh V Dinh; Serena Mraz; Javier Gomez Vera; Dorothea von Bredow; Alfred von Krempelhuber; Siegfried Roesch; Garth Virgin; Nathaly Arndtz-Wiedemann; Thomas Peter Meyer; Darja Schmidt; Richard Nichols; Philip Young; Paul Chaplin Journal: PLoS One Date: 2015-10-06 Impact factor: 3.240
Authors: Edgar Turner Overton; Jack Stapleton; Ian Frank; Shawn Hassler; Paul A Goepfert; David Barker; Eva Wagner; Alfred von Krempelhuber; Garth Virgin; Thomas Peter Meyer; Jutta Müller; Nicole Bädeker; Robert Grünert; Philip Young; Siegfried Rösch; Jane Maclennan; Nathaly Arndtz-Wiedemann; Paul Chaplin Journal: Open Forum Infect Dis Date: 2015-05-05 Impact factor: 3.835
Authors: Richard N Greenberg; Christine M Hay; Jack T Stapleton; Thomas C Marbury; Eva Wagner; Eva Kreitmeir; Siegfried Röesch; Alfred von Krempelhuber; Philip Young; Richard Nichols; Thomas P Meyer; Darja Schmidt; Josef Weigl; Garth Virgin; Nathaly Arndtz-Wiedemann; Paul Chaplin Journal: PLoS One Date: 2016-06-21 Impact factor: 3.752